Angiotensin II and vascular endothelial growth factor in the vitreous fluid of patients with proliferative diabetic retinopathy

被引:113
作者
Funatsu, H
Yamashita, H
Nakanishi, Y
Ori, SH
机构
[1] Tokyo Womens Med Univ, Ctr Diabet, Dept Ophthalmol, Shinjuku Ku, Tokyo 1628666, Japan
[2] Yamagata Univ, Sch Med, Dept Ophthalmol, Yamagata 990, Japan
关键词
D O I
10.1136/bjo.86.3.311
中图分类号
R77 [眼科学];
学科分类号
100212 ;
摘要
Aims: To investigate the correlation between the level of angiotensin II and vascular endothelial growth factor (VEGF) in the vitreous fluid and the severity of proliferative diabetic retinopathy (PDR). Methods: During vitreoretinal surgery at the Tokyo Women's Medical University, vitreous fluid samples were obtained from 51 eyes of diabetic, patients with PDR, six eyes of diabetic patients without retinopathy, and 16 eyes of non-diabetic patients with ocular disease (controls). The VEGF levels in vitreous fluid and plasma were determined by enzyme linked immunosorbent assay, while angiotensin II levels were measured by radioimmunoassay. Results: The vitreous fluid levels of VEGF and angiotensin II were significantly higher in patients with PDR than in non-diabetic patients or diabetic patients without retinopathy (all p<0.0001). The vitreous fluid level of angiotensin II was significantly correlated with that of VEGF (p<0.0001), and the vitreous concentrations of both VEGF and angiotensin II were significantly higher in patients with active PDR than in those with quiescent PDR (p<0.0001 and p=0.0005, respectively). Conclusion: The authors found that both angiotensin II and VEGF levels were significantly higher in the vitreous fluid of patients with PDR than in that of non-diabetic patients or diabetic patients without retinopathy, and that the levels of both angiotensin II and VEGF were elevated in the active stage of PDR. These findings suggest that angiotensin II contributes to the development and progression of PDR in combination with VEGF.
引用
收藏
页码:311 / 315
页数:5
相关论文
共 30 条
[1]   VASCULAR ENDOTHELIAL GROWTH-FACTOR IN OCULAR FLUID OF PATIENTS WITH DIABETIC-RETINOPATHY AND OTHER RETINAL DISORDERS [J].
AIELLO, LP ;
AVERY, RL ;
ARRIGG, PG ;
KEYT, BA ;
JAMPEL, HD ;
SHAH, ST ;
PASQUALE, LR ;
THIEME, H ;
IWAMOTO, MA ;
PARK, JE ;
NGUYEN, HV ;
AIELLO, LM ;
FERRARA, N ;
KING, GL .
NEW ENGLAND JOURNAL OF MEDICINE, 1994, 331 (22) :1480-1487
[2]  
[Anonymous], 1991, Ophthalmology, V98, P823
[3]  
[Anonymous], 1991, Ophthalmology, V98, P786
[4]  
BATTEGAY EJ, 1995, J MOL MED, V73, P333
[5]   Effect of lisinopril on progression of retinopathy in normotensive people with type 1 diabetes [J].
Chaturvedi, N ;
Sjolie, AK ;
Stephenson, JM ;
Abrahamian, H ;
Keipes, M ;
Castellarin, A ;
Rogulja-Pepeonik, Z ;
Fuller, JH .
LANCET, 1998, 351 (9095) :28-31
[6]   Upregulation of vascular endothelial growth factor by angiotensin II in rat heart endothelial cells [J].
Chua, CC ;
Hamdy, RC ;
Chua, BHL .
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH, 1998, 1401 (02) :187-194
[7]   ANGIOTENSIN-II INDUCES SMOOTH-MUSCLE CELL-PROLIFERATION IN THE NORMAL AND INJURED RAT ARTERIAL-WALL [J].
DAEMEN, MJAP ;
LOMBARDI, DM ;
BOSMAN, FT ;
SCHWARTZ, SM .
CIRCULATION RESEARCH, 1991, 68 (02) :450-456
[8]   RENIN, PRORENIN, AND IMMUNOREACTIVE RENIN IN VITREOUS FLUID FROM EYES WITH AND WITHOUT DIABETIC-RETINOPATHY [J].
DANSER, AHJ ;
VANDENDORPEL, MA ;
DEINUM, J ;
DERKX, FHM ;
FRANKEN, AAM ;
PEPERKAMP, E ;
DEJONG, PTVM ;
SCHALEKAMP, MADH .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1989, 68 (01) :160-167
[9]  
DANSER AHJ, 1994, INVEST OPHTH VIS SCI, V35, P1008
[10]   IDENTIFICATION AND QUANTIFICATION OF RENIN AND PRORENIN IN THE BOVINE EYE [J].
DEINUM, J ;
DERKX, FHM ;
DANSER, AHJ ;
SCHALEKAMP, MADH .
ENDOCRINOLOGY, 1990, 126 (03) :1673-1682